LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

Search

Natera Inc

Fermé

SecteurSoins de santé

199 0.5

Résumé

Variation du prix de l'action

24h

Actuel

Min

197.65

Max

200.14

Chiffres clés

By Trading Economics

Revenu

-34M

-101M

Ventes

45M

547M

Marge bénéficiaire

-18.467

Employés

4,424

EBITDA

-33M

-90M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+13.01% upside

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

8.6B

27B

Ouverture précédente

198.5

Clôture précédente

199

Score Technique

By Trading Central

Confiance

Bullish Evidence

Natera Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

7 nov. 2025, 21:06 UTC

Principaux Mouvements du Marché

JBS Down After Trump Calls for Probe into Meat-Packing Companies

8 nov. 2025, 18:10 UTC

Résultats

10 Defensive Stocks with Market-Beating Yields -- Barrons.com

8 nov. 2025, 13:10 UTC

Acquisitions, Fusions, Rachats

Pfizer and Metsera Reach Deal Expected to Top $10 Billion -- Update

8 nov. 2025, 12:00 UTC

Résultats

Apple's iPhone Air Is a Marketing Win and a Sales Flop -- WSJ

8 nov. 2025, 10:30 UTC

Résultats

Why Car Insurers Are Under Pressure to Cut Rates -- Heard on the Street -- WSJ

8 nov. 2025, 03:50 UTC

Acquisitions, Fusions, Rachats

Pfizer and Metsera Reach Deal Expected to Top $10 Billion -- 4th Update

8 nov. 2025, 03:41 UTC

Acquisitions, Fusions, Rachats

Pfizer and Metsera Reach Deal Expected to Top $10 Billion -- WSJ

8 nov. 2025, 03:07 UTC

Acquisitions, Fusions, Rachats

Pfizer and Metsera Reach Deal Worth Up to $10 Billion -- WSJ

7 nov. 2025, 22:36 UTC

Résultats

McDonald's Stock Challenged By a Tougher Economy, Analyst Says. Plus, Marriott, Snowflake, and More. -- Barrons.com

7 nov. 2025, 22:22 UTC

Résultats

The Score: GM, Tesla, Palantir, American Airlines and More Stocks That Defined the Week -- WSJ

7 nov. 2025, 22:03 UTC

Résultats

Constellation Software 3Q Rev $2.95B >CSU.T

7 nov. 2025, 22:03 UTC

Résultats

Constellation Software 3Q Net $210M >CSU.T

7 nov. 2025, 22:03 UTC

Résultats

Constellation Software 3Q EPS $9.89 >CSU.T

7 nov. 2025, 21:50 UTC

Market Talk

Financial Services Roundup: Market Talk

7 nov. 2025, 21:50 UTC

Market Talk

Health Care Roundup: Market Talk

7 nov. 2025, 20:59 UTC

Résultats

Palantir's CEO Says His Earnings Were the Best Ever. They Weren't Even the Best of the Week. -- Barrons.com

7 nov. 2025, 20:26 UTC

Market Talk

Natural U.S. Gas Futures Extend Rally to Three Weeks -- Market Talk

7 nov. 2025, 20:22 UTC

Résultats

Free-Spending Big Tech Dominates Earnings. As for the Rest: Don't Miss. -- Barrons.com

7 nov. 2025, 20:04 UTC

Market Talk

Oil Futures Close Choppy Week With Losses -- Market Talk

7 nov. 2025, 19:34 UTC

Market Talk

Gold Posts Small Gain for Week -- Market Talk

7 nov. 2025, 19:31 UTC

Market Talk
Acquisitions, Fusions, Rachats

Prices of Gas-Fired Power Plants Have Room to Grow -- Market Talk

7 nov. 2025, 19:17 UTC

Résultats

These Stocks Are Moving the Most Today: Tesla, Expedia, Take-Two, Block, Affirm, Sunrun, Globus Medical, JFrog, and More -- Barrons.com

7 nov. 2025, 19:09 UTC

Résultats

Wendy's Turnaround Won't Be Easy. Earnings, and the Stock, Tell the Story. -- Barrons.com

7 nov. 2025, 19:08 UTC

Résultats

KKR Defied Private-Equity Fundraising Slump in the Third Quarter -- WSJ

7 nov. 2025, 18:31 UTC

Market Talk

U.S. Oil RIg Count Unchanged at 414 -- Market Talk

7 nov. 2025, 17:27 UTC

Market Talk

EPA Announces New Exemptions to Biofuel Blending Rules -- Market Talk

7 nov. 2025, 17:20 UTC

Market Talk

Eli Lilly GLP-1 Deal with Trump Administration Provides Net Boost -- Market Talk

7 nov. 2025, 17:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

7 nov. 2025, 17:20 UTC

Market Talk

Financial Services Roundup: Market Talk

7 nov. 2025, 17:20 UTC

Market Talk

Health Care Roundup: Market Talk

Comparaison

Variation de prix

Natera Inc prévision

Objectif de Prix

By TipRanks

13.01% hausse

Prévisions sur 12 Mois

Moyen 225.54 USD  13.01%

Haut 268 USD

Bas 172 USD

Basé sur 15 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

15 ratings

13

Achat

2

Maintien

0

Vente

Score Technique

By Trading Central

153.79 / N/ASupport & Résistance

Court Terme

Bullish Evidence

Moyen Terme

Strong Bullish Evidence

Long Terme

Bullish Evidence

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Natera Inc

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.
help-icon Live chat